ALIM Key Statistics, Chart & Performance
The current stock price of ALIM is 5.54 USD. In the past month the price decreased by -0.72%. In the past year, price increased by 66.87%.
ALIM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.19 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.63 | 515.95B | ||
| MRK | MERCK & CO. INC. | 12.29 | 268.70B | ||
| PFE | PFIZER INC | 7.84 | 142.71B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.54 | 114.09B | ||
| ZTS | ZOETIS INC | 19.59 | 54.74B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.8 | 23.26B | ||
| VTRS | VIATRIS INC | 5.67 | 15.22B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.23 | 12.03B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.83B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.45B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.22B |
Related stock screener links
About ALIM
Company Profile
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. The company is headquartered in Alpharetta, Georgia and currently employs 159 full-time employees. The company went IPO on 2010-04-22. The company is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.
Company Info
ALIMERA SCIENCES INC
Ste 290, 6120 Windward Parkway
Alpharetta GEORGIA 30005 US
CEO: Richard S. Eiswirth Jr.
Employees: 159
Phone: 16789905740
ALIMERA SCIENCES INC / ALIM FAQ
What does ALIM do?
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. The company is headquartered in Alpharetta, Georgia and currently employs 159 full-time employees. The company went IPO on 2010-04-22. The company is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.
Can you provide the latest stock price for ALIMERA SCIENCES INC?
The current stock price of ALIM is 5.54 USD. The price decreased by -0.18% in the last trading session.
What is the dividend status of ALIMERA SCIENCES INC?
ALIM does not pay a dividend.
What is the ChartMill rating of ALIMERA SCIENCES INC stock?
ALIM has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is ALIMERA SCIENCES INC (ALIM) expected to grow?
The Revenue of ALIMERA SCIENCES INC (ALIM) is expected to grow by 34.43% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for ALIMERA SCIENCES INC?
ALIMERA SCIENCES INC (ALIM) currently has 159 employees.
ALIM Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ALIM. When comparing the yearly performance of all stocks, ALIM is one of the better performing stocks in the market, outperforming 96.39% of all stocks.
ALIM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ALIM. ALIM may be in some trouble as it scores bad on both profitability and health.
ALIM Financial Highlights
Over the last trailing twelve months ALIM reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 90.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.16% | ||
| ROE | -39.38% | ||
| Debt/Equity | 1.8 |
ALIM Forecast & Estimates
9 analysts have analysed ALIM and the average price target is 5.78 USD. This implies a price increase of 4.33% is expected in the next year compared to the current price of 5.54.
For the next year, analysts expect an EPS growth of 94.02% and a revenue growth 34.43% for ALIM